PRTA Prothena Corporation plc

64.76
-0.29  -0%
Previous Close 65.05
Open 64.68
Price To book 5.09
Market Cap 2478694246
Shares 38,275,081
Volume 159,790
Short Ratio 30.05
Av. Daily Volume 235,985

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned for 2Q 2017.
PRX002 (PASADENA)
Parkinson's disease
Phase 1b data due October 2017.
PRX003
Psoriatic Arthritis
Phase 3 trial fully enrolled - noted August 8, 2017.
NEOD001 VITAL
AL Amyloidosis
Phase 2b data due 2Q 2018.
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction